 Home > Active Ingredient News > Endocrine System > Diabetes Obes Metab: Analysis of the efficacy of soxgliflozin in patients with type 2 diabetes

Diabetes Obes Metab: Analysis of the efficacy of soxgliflozin in patients with type 2 diabetes

 Last Update: 2021-10-09
 Source: Internet
 Author: User

Tags

vet supply source

vitamin heart

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, a research article was published in Diabetes Obesity & Metabolism, an authoritative journal in the field of metabolic endocrine diseases.
Researchers aimed to evaluate the efficacy and safety of Soxaggliflozin in patients with type 2 diabetes
.

diabetes

Researchers searched Medline, Embase, Cochrane Library and grey literature resources, and the search time is up to August 2021, to obtain randomized controlled trials comparing soxgliflozin with placebo or other anti-diabetic drugs in patients with type 2 diabetes.
(RCT)
.

The main outcome of the study was the change in HbA1c from baseline

The researchers included 11 RCTs in the meta-analysis, including 16,411 participants
.

Compared with placebo, soxgliflozin reduced HbA1c (WMD is -0.

Compared with placebo, Soxaggliflozin reduced myocardial infarction (OR of 0.
72, 95% CI of 0.
54 to 0.
97) and heart failure (OR of 0.
68, 95% CI of 0.
58 to 0.
79), and it was effective in all-cause mortality , heart vascular mortality and stroke impact is neutral
.

In terms of the incidence of serious adverse events, hypoglycemia and diabetic ketoacidosis, soxgliflozin treatment is safe

Heart vascular stroke hypoglycemia infection

It can be seen that Soxaggliflozin can reduce blood sugar, weight and systolic blood pressure, and has a beneficial effect on heart failure and myocardial infarction
.

Its overall safety is comparable to other SGLT-2 inhibitors

Soxaggliflozin can reduce blood sugar, weight and systolic blood pressure, and has a beneficial effect on heart failure and myocardial infarction
.
Its overall safety is comparable to other SGLT-2 inhibitors
.
Original Source: Sotagliflozin for patients with of the type 2 Diabetes: A Systematic Review and Meta-the Analysis in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

lodine iodine crystal wholesales

CAS No.: 7553-56-2

$2-2.2/MT EXW

High quality HCG powder CAS 56832-34-9 HCG 5000iu vial BETA-HCG

CAS No.: 56832-34-9

Pharmaceutical Grade

$40-45/UNIT FOB

Pharmaceutical Grade 99% Potassium Iodide in Good Price CAS 7681-11-0

CAS No.: 7681-11-0

Chemical Grade

$3.5-4/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.